Use

This test is intended for use in conjunction with clinical presentation and other laboratory markers of disease progress for the clinical management of HIV‑1 infected patients. It can be used to assess patient prognosis by measuring the baseline HIV‑1 RNA level, or to monitor the effects of antiretroviral therapy by measuring changes in EDTA plasma HIV‑1 RNA levels during the course of treatment. Additionally, the emergence of integrase drug resistance mutations can be observed and inform therapy adjustments by amplifying and sequencing the HIV‑1 integrase gene, reporting mutations at positions associated with integrase inhibitor drug resistance.